Cannabidiol as a Promising Adjuvant Therapy for Estrogen Receptor-Positive Breast Tumors: Unveiling Its Benefits with Aromatase Inhibitors

SIMPLE SUMMARY: Estrogen receptor-positive (ER(+)) breast cancer is the most prevalent breast cancer subtype, accounting for 70–85% of all cases. The combination of endocrine therapy, such as aromatase inhibitors (AIs), with target therapy is one of the most recent approaches, but its effectiveness...

Descripción completa

Detalles Bibliográficos
Autores principales: Almeida, Cristina Ferreira, Teixeira, Natércia, Valente, Maria João, Vinggaard, Anne Marie, Correia-da-Silva, Georgina, Amaral, Cristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177097/
https://www.ncbi.nlm.nih.gov/pubmed/37173983
http://dx.doi.org/10.3390/cancers15092517

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177097/
https://www.ncbi.nlm.nih.gov/pubmed/37173983
http://dx.doi.org/10.3390/cancers15092517

Ejemplares similares